Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment
ConclusionsAberrant activation of multiple pathways and low baseline tumor-infiltrating B cells are related to HER2 + BC trastuzumab-based recurrence, which primarily affects the antitumor activity of trastuzumab.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | HER2 | Herceptin | Statistics | Study